Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study

Lung Cancer

Volumn 32, Issue 2, 2001, Pages 179-187

  Kakolyris, S ^a   Papadakis, E ^b   Tsiafaki, X ^c   Kalofonos, C ^d   Rapti, A ^b   Toubis, M ^b   Bania, E ^b   Kouroussis, Ch ^a   Chainis, K ^e   Androulakis, N ^a   Agelaki, S ^a   Sarra, E ^a   Vardakis, N ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b KAT HOSPITAL   (Greece)

^c SISMANOGLIO HOSPITAL   (Greece)

^d UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^e General Hospital of Corfu   (Greece)

Author keywords

Docetaxel; Gemcitabine; NSCLC; Salvage treatment

Indexed keywords

DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; LIFE TABLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; RECOMBINANT PROTEINS; SALVAGE THERAPY; SURVIVAL ANALYSIS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 0035040812     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00212-9     Document Type: Article

References (30)

1. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer
2. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer
3. A phase II study of CPT-11, a new camptothecin derivative for previously untreated non-small cell lung cancer
4. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer
5. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a Phase II study
6. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small cell lung cancer
7. Second-line chemotherapy with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer
8. An early phase II study of CPT-11 for primary lung cancer
9. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer
10. Docetaxel and granulocyte colony-stimulating factor in patients with advanced NSCLC previously treated with platinum-based chemotherapy: a multicenter phase II trial
11. Docetaxel in platinum-treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival in a multicenter trial
12. Salvage therapy with gemcitabine (GEM) in pretreated, advanced non-small cell lung cancer (NSCLC)
13. Activity of gemcitabine (GEM) in cisplatin-pretreated patients with advanced non-small cell lung cancer (NSCLC)
14. Second line gemcitabine (GEM) therapy in non-small cell lung cancer (NSCLC) stage IIIB and IV
15. Gemcitabine (GEM) in platinum (PLAT) treated non-small cell lung cancer (NSCLC)
16. Phase II randomized multicenter trial of two dose schedules of gemcitabine as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC)
17. Salvage therapy with gemcitabine in advanced non-small cell lung cancer (NSCLC) progressing after prior carboplatin-paclitaxel (C-P)
18. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
19. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens
20. Studies with PR56976 (Taxotere): a semisynthetic analogue of taxol
21. Relationships between the structure of taxol analogues and their antimitotic activity
22. Gemcitabine: Preclinical pharmacology and mechanisms of action
23. Preclinical, pharmacologic and phase I studies of gemcitabine
24. Efficacy and safety profile of gemcitabine in advanced non-small cell lung cancer: A phase II study
25. Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial
26. Non-parametric estimation from incomplete observations
27. Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial
28. Ras oncogene induced sensitization to 1-beta-D-arabinofuranosylcytosine